SynthesisMedicine2019
Prognostic value of serum uric acid in patients with acute heart failure: A meta-analysis.
Synthesis in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Uric acid is a biomarker for heart failure, but not therapeutic target: result from a comprehensive meta-analysis.ESC heart failure · 2024Pooled it
- Relationship between serum uric acid levels and uric acid lowering therapy with the prognosis of patients with heart failure with preserved ejection fraction: a meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Effect of Uric Acid-Lowering Agents on Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Frontiers in cardiovascular medicine · 2021Pooled it
- Serum Uric Acid and Risk of Chronic Heart Failure: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.European heart journal · 2022Trial
- Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME.Diabetes, obesity & metabolism · 2020Trial
- Hyperuricemia Reflects Cardiometabolic Burden Rather than Left Ventricular Systolic Dysfunction Across Heart Failure Phenotypes: Insights from a Real-World Acute Heart Failure Cohort.Journal of clinical medicine · 2026Article
- Clinical Determinants of Serum Uric Acid Levels in Patients with Obesity and Hypertension.Journal of clinical medicine · 2026Article
- Copeptin, Routine Laboratory Parameters, and Ischemic Etiology of Heart Failure Predict Outcomes in Elderly Patients with Decompensated Heart Failure.Biomedicines · 2025Article
- Hyperuricemia and adverse outcomes in patients with cardiorenal syndrome: A nationwide prospective cohort study in China.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Prognostic Markers of Adverse Outcomes in Acute Heart Failure: Use of Machine Learning and Network Analysis with Real Clinical Data.Journal of clinical medicine · 2025Article
- Impact of serum uric acid to high-density lipoprotein cholesterol ratio on short-term outcomes in acute decompensated heart failure: a cohort study in Jiangxi Province, China.Frontiers in endocrinology · 2025Article
- Impact of Hyperuricemia on Clinical Outcomes in Sepsis Patients: A Retrospective Cohort Study.Journal of clinical medicine · 2024Article
- Treatment with Rasburicase in Hospitalized Patients with Cardiorenal Syndrome: Old Treatment, New Scenario.International journal of molecular sciences · 2024Article
- Review
- Article
- Prevalence of Hyperuricemia and Its Association with Cardiovascular Risk Factors and Subclinical Target Organ Damage.Journal of clinical medicine · 2022Article
- The effect of SGLT-2i administration on red blood cell distribution width in patients with heart failure and type 2 diabetes mellitus: A randomized study.Frontiers in cardiovascular medicine · 2022Article
- Hyperuricemia as a Marker of Reduced Left Ventricular Ejection Fraction in Patients with Atrial Fibrillation: Results of the POL-AF Registry Study.Journal of clinical medicine · 2021Article
- Clinical Implications of Uric Acid in Heart Failure: A Comprehensive Review.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConflicting results have been reported on the prognostic significance of serum uric acid (SUA) in patients with acute heart failure (AHF). This meta-analysis aimed to determine the prognostic significance of SUA level in patients with AHF.
methodsWe made a comprehensive literature search in Pubmed and Embase databases from inception to April 6, 2018. All available observational studies or post hoc analysis of randomized controlled trial that evaluated the prognostic value of SUA level in patients with AHF were eligible. Outcome of interests were all-cause mortality and the combined endpoint of death or readmission. Prognostic values of SUA level were summarized as higher vs lower SUA category or per 1 mg/ml SUA rise.
resultsTen studies involving 12,854 AHF patients were identified and analyzed. AHF patients with the highest SUA level had an increased risk of all-cause mortality (risk ratio [RR] 1.43; 95% confidence intervals [CI] 1.31-1.56) and combined endpoint of death or readmission (RR 1.68; 95% CI 1.33-2.13) after adjusting potential variables. In addition, per 1 mg/ml SUA rise significantly increased by 11% and 12% higher risk all-cause mortality and combined endpoint of death or readmission, respectively. A leave out 1 study sensitivity analysis confirmed the reliability of the pooling effect sizes.
conclusionThis meta-analysis indicates that elevated SUA level independently predicts all-cause mortality and the combined endpoint of death or readmission in AHF patients. Measurement of SUA level may improve risk stratification of adverse outcomes in these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.